Gilead Sciences on Thursday posted a higher-than-expected third-quarter profit on the back of strong demand for its HIV and cancer drugs, which helped offset lower sales of its COVID-19 antiviral drug and acquisition expenses.
Prognosis has certainly changed in past 10 years. We have been able to have an excellent control of disease, and patients are living longer, says the co-author of a recent review.
A phase 2 trial of lutetium-octreotate in patients with unresectable progressive pancreatic neuroendocrine tumors shows nearly double the 1-year survival rate compared with sunitinib at standard dose.